Investor Presentaiton
R&D investor presentation
In the phase 2 trial, AM833 plus lifestyle intervention decreased
weight by up to 10.8% as monotherapy after 26 weeks
Dose-finding phase 2 trial for AM833
38
Weight loss for AM833 plus lifestyle intervention² at
different doses with increased weight loss for higher doses³
Placebo
AM833
AM833
Lira
0.6mg
AM833 4.5 mg QW
2.4mg
3.0mg
% change in
body weight
AM833
AM833
AM833
AM833 2.4 mg QW
0.3mg
1.2mg
4.5mg
0
AM833 1.2 mg QW
706 people¹ with
obesity or overweight
Mean baseline: 107.4 kg
-2
AM833 0.6 mg QW
with co-morbidities and
HbA1c < 6.5%
-4
AM833 0.3 mg QW
Liraglutide, 3.0 mg QD
-6
Placebo
-8
26-week treatment
-10
- 10.8%
-12
0 2 4
6
Primary endpoint
Change from baseline to week 26 in body weight (%)
Safety
1 Obesity is defined as BMI ≥ 30.0 and overweight as BMI 27.0-29.9 kg/m²
8 10 12 14 16 18 20 22 24 26
Weeks
AM833 appeared to have a safe and well-tolerated
profile at all dose levels
2 Lifestyle intervention is defined as counselling for a reduced-calorie diet and increased
physical activity
3 Data based on the trial product estimand
novo nordiskView entire presentation